



BRUSSELS DEBATE

Tuesday, 30 May 2023 from 13:00 until 14:30 hrs

**European Parliament
Altiero-Spinelli-Building - Restaurant des Députés, Salon**

“Helping innovation reach patients”

From shortages through to patients access to new medicines in Europe – will the proposed revision to the pharmaceutical legislation help ?

Improving the availability, affordability and accessibility for patients to new medicines in Europe is at heart of the EU's revision of the general pharmaceutical legislation.

Poor patient access can have many root-causes. Will the European Commission's new proposal deliver more fairness from Berlin to Bucharest? What impact will it have for chronic diseases, such as cancer and cardiovascular disease? Will the new EU joint action on HTA complement the goal to improve access to new innovations? Will Europe become more or less attractive for future investments including biomanufacturing facilities?

Welcome and Introduction:

- **Michael GAHLER MEP, President of the Kangaroo Group**

Speakers:

- **Susana SOLÍS PÉREZ MEP, Renew Europe / Spain, Member of the Committee on Regional Development and Member of the Subcommittee on Public Health**
- **Tomislav SOKOL MEP, EPP/Croatia, Member of the Committee on the Internal Market and Member on the COVID-19 pandemic: lessons learned and recommendations for the Future**

- **Csaba KONTOR, Health Attaché, Permanent Representation of Hungary to the EU**
- **Stefan GJJSSELS, Chair, Patient Expert Center**
- **Nabil DAOUD, President of Eli Lilly Spain, Portugal and Greece, Eli Lilly & Company**

(this debate is held under Chatham House Rules)

